DR info

臨床試験数 : 133 / 薬物数 : 186 - (DrugBank : 67) / 標的遺伝子数 : 79 - 標的パスウェイ数 : 190

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

11C]-methionine
   Guys' and St. Thomas' NHS Foundation Trust
      2011   -   EUCTR2010-019759-23-GB   United Kingdom;
2-amino-4-(methyl[11C]sulfanyl)butanoic acid
   Guys' and St. Thomas' NHS Foundation Trust
      2011   -   EUCTR2010-019759-23-GB   United Kingdom;
755nm Alexandrite Laser
   Massachusetts General Hospital
      2021   Phase 1   NCT04730583   -
980nm laser
   Massachusetts General Hospital
      2021   Phase 1   NCT04730583   -
AL2846 capsules
   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
      2021   Phase 1/Phase 2   NCT05011019   China;
AMN107
   Gustave Roussy
      2013   Phase 2   EUCTR2012-003005-10-DK   Denmark;France;Netherlands;Spain;Switzerland;
AR-42
   Massachusetts Eye and Ear Infirmary
      2015   Early Phase 1   NCT02282917   United States;
AZD2014
   Massachusetts General Hospital
      2016   Phase 2   NCT02831257   United States;
AZD6244
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-005607-39-IT   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States;
   AstraZeneca AB
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-NL   Germany;Italy;Netherlands;Russian Federation;Spain;United States;
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-ES   Germany;Italy;Netherlands;Russian Federation;Spain;United States;
      2021   Phase 3   EUCTR2020-005607-39-ES   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States;
      2021   Phase 1;Phase 2   EUCTR2020-005608-20-DE   Germany;Italy;Netherlands;Russian Federation;Spain;United States;
      2021   Phase 1   EUCTR2020-005648-52-PL   Poland;Russian Federation;Spain;United States;
   National Cancer Institute (NCI)
      2011   Phase 1/Phase 2   NCT01362803   United States;
Abemaciclib
   National Cancer Institute (NCI)
      2021   Phase 1/Phase 2   NCT04750928   United States;
Acetaminophen
   AstraZeneca
      2018   Phase 1   NCT03649165   United States;
Afinitor
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2011-002228-42-FR   France;
Aminolevulinic acid
   Harry T Whelan, MD
      2016   Phase 2   NCT02728388   United States;
Antigen-specific T cells CART/CTL and DCvac
   Shenzhen Geno-Immune Medical Institute
      2019   Phase 1/Phase 2   NCT04085159   China;
Aspirin
   Massachusetts Eye and Ear Infirmary
      2018   Phase 2   NCT03079999   United States;
Axitinib
   NYU Langone Health
      2014   Phase 2   NCT02129647   United States;
Bevacizumab
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States;
   National Cancer Institute (NCI)
      2010   Phase 2   NCT01207687   United States;
   Northwestern University
      2010   Phase 2   NCT01125046   United States;
   Sarcoma Alliance for Research through Collaboration
      2012   Phase 2   NCT01661283   United States;
   Shanghai Ninth People's Hospital affiliated to Shanghai JiaoTong University, School of Medicine
      2018   -   ChiCTR1800016040   China;
   University of Alabama at Birmingham
      2013   Phase 2   NCT01767792   United States;
Bevacizumab (Genitical Recombination)
   Kiyoshi Saito
      2019   Phase 2   JPRN-JapicCTI-194999   Japan;
Binimetinib
   University of Alabama at Birmingham
      2017   Phase 2   NCT03231306   United States;
Bony Toxicity
   National Cancer Institute (NCI)
      2008   Phase 1   NCT00727233   United States;
Brigatinib
   Scott R. Plotkin, MD, PhD
      2020   Phase 2   NCT04374305   United States;
Cabozantinib
   University of Alabama at Birmingham
      2014   Phase 2   NCT02101736   United States;
Carboplatin
   Children's Oncology Group
      2006   Phase 1   NCT00352495   Canada;United States;
   National Cancer Institute (NCI)
      2020   Phase 3   NCT04166409   Canada;Puerto Rico;United States;
      2019   Phase 3   NCT03871257   Canada;Puerto Rico;United States;
Cediranib Maleate
   National Cancer Institute (NCI)
      2006   Phase 2   NCT00326872   United States;
Celecoxib (Celebrex)
   Spectrum Health Hospitals
      2008   Phase 2   NCT00846430   United States;
Cetuximab
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States;
Cholecalciferol
   University of Utah
      2017   Phase 2   NCT01968590   Canada;Germany;United States;
Control Group
   University of Alabama at Birmingham
      2016   -   NCT02718131   Australia;United States;
Conventional surgery
   Sarcoma Alliance for Research through Collaboration
      2005   Phase 2   NCT00304083   Canada;United States;
Crizotinib
   University of Alabama at Birmingham
      2020   Phase 2   NCT04283669   United States;
Dabrafenib
   Novartis Pharmaceuticals
      2019   Phase 4   NCT03975829   Canada;France;Spain;United Kingdom;United States;
   Pediatric Brain Tumor Consortium
      2019   Phase 1/Phase 2   NCT04201457   United States;
Dexmedetomidine
   Medical College of Wisconsin
      2018   Phase 4   NCT03513757   United States;
Diclofenac Sodium
   Fundação Educacional Serra dos Órgãos
      2017   Phase 2   NCT03090971   Brazil;
Doxorubicin hydrochloride
   Sarcoma Alliance for Research through Collaboration
      2005   Phase 2   NCT00304083   Canada;United States;
Endostatin
   Beijing Tiantan Hospital
      2014   Phase 2   NCT02104323   China;
Etoposide
   Sarcoma Alliance for Research through Collaboration
      2005   Phase 2   NCT00304083   Canada;United States;
Everolimus
   Novartis Pharmaceuticals
      -   Phase 4   EUCTR2016-001563-36-Outside-EU/EEA   Israel;
   Sarcoma Alliance for Research through Collaboration
      2012   Phase 2   NCT01661283   United States;
   The University of Texas Health Science Center, Houston
      2015   Phase 2   NCT02332902   United States;
Everolimus (RAD001)
   Novartis Pharmaceuticals
      2012   Phase 2   NCT01365468   Israel;
Everolimus (RAD001) , Afinitor®
   New York University School of Medicine
      2011   Phase 2   NCT01419639   United States;
Evérolimus
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2011-002228-42-FR   France;
FCN-159
   Shanghai Fosun Pharmaceutical Development Co, Ltd.
      2021   Phase 1/Phase 2   NCT04954001   -
Filgrastim
   Sarcoma Alliance for Research through Collaboration
      2005   Phase 2   NCT00304083   Canada;United States;
Fludeoxyglucose F 18
   Children's Hospital of Philadelphia
      2002   -   NCT00060008   United States;
GLIVEC 100 mg comprimidos recubiertos con película
   HOSPITAL SANT JOAN DE DÉU
      2010   -   EUCTR2009-016922-15-ES   Spain;
GLIVEC 400 mg comprimidos recubiertos con película
   HOSPITAL SANT JOAN DE DÉU
      2010   -   EUCTR2009-016922-15-ES   Spain;
Gadolinium contrast
   Washington University School of Medicine
      2013   -   NCT02584413   United States;
Gadopentetate
   Children's Hospital of Philadelphia
      2002   -   NCT00060008   United States;
Gleevec
   Indiana University
      2006   Phase 2   NCT01673009   United States;
   Kent Robertson
      2012   Phase 1/Phase 2   NCT01140360   United States;
Glycopyrrolate
   Medical College of Wisconsin
      2018   Phase 4   NCT03513757   United States;
Gold
   Shanghai 9th People's Hospital Affiliated to Shanghai Jiaotong University School of Medicine
      2016   -   ChiCTR-DDD-16009551   China;
   Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
      2020   Phase 0   ChiCTR2000036770   China;
Hydroxychloroquine
   Pediatric Brain Tumor Consortium
      2019   Phase 1/Phase 2   NCT04201457   United States;
INFUSE Bone Graft (BMP-2)
   University of Alabama at Birmingham
      2016   -   NCT02718131   Australia;United States;
Icotinib
   Li Peng
      2016   Phase 2   NCT02934256   China;
Ifosfamide
   Sarcoma Alliance for Research through Collaboration
      2005   Phase 2   NCT00304083   Canada;United States;
Imatinib Mesylate
   Indiana University
      2018   Phase 2   NCT03688568   United States;
   St. Justine's Hospital
      2014   Phase 2   NCT02177825   Canada;
Imiquimod Cream
   Massachusetts General Hospital
      2009   Phase 1   NCT00865644   United States;
Isotonic sodium chloride solution
   Kiyoshi Saito
      2019   Phase 2   JPRN-JapicCTI-194999   Japan;
Koselugo
   AstraZeneca AB
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-NL   Germany;Italy;Netherlands;Russian Federation;Spain;United States;
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-ES   Germany;Italy;Netherlands;Russian Federation;Spain;United States;
      2021   Phase 1   EUCTR2020-005648-52-PL   Poland;Russian Federation;Spain;United States;
Kybella
   Massachusetts General Hospital
      2021   Phase 1   NCT04730583   -
Lamotrigin beta
   Technische Universität München, Fakultät für Medizin
      2018   Phase 2   EUCTR2016-005022-10-DE   Germany;
Lamotrigine
   Erasmus Medical Center
      2014   Phase 2/Phase 3   NCT02256124   Belgium;Netherlands;Spain;
Lamotrigine dispers
   Erasmus MC
      2018   Phase 2   EUCTR2013-003405-26-DK   Belgium;Denmark;Netherlands;Spain;
      2017   Phase 2   EUCTR2013-003405-26-ES   Belgium;Netherlands;Spain;
      2015   -   EUCTR2013-003405-26-BE   Belgium;Netherlands;
      2014   -   EUCTR2013-003405-26-NL   Netherlands;
Lapatinib
   New York University School of Medicine
      2009   Phase 2   NCT00973739   United States;
   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      2009   Early Phase 1   NCT00863122   United States;
Lenalidomide
   National Cancer Institute (NCI)
      2012   Phase 2   NCT01553149   Australia;Canada;New Zealand;United States;
Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 1
   Harry T Whelan, MD
      2012   Phase 1   NCT01682811   United States;
Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 2
   Harry T Whelan, MD
      2012   Phase 1   NCT01682811   United States;
Levulan (5-aminolevulinic acid) photodynamic therapy - Dose level 3
   Harry T Whelan, MD
      2012   Phase 1   NCT01682811   United States;
Lidocaine Injectable Solution
   Medical College of Wisconsin
      2018   Phase 4   NCT03513757   United States;
Lovastatin
   University of California, Los Angeles
      2009   Phase 1   NCT00352599   United States;
   University of Coimbra
      2019   -   NCT03826940   Portugal;
   Vanderbilt University
      2016   Phase 2   NCT02964884   United States;
Lovastatin ™
   University of Alabama at Birmingham
      2009   Phase 2   NCT00853580   Australia;United States;
MRI, FDG-PET/CT scans
   National Cancer Institute (NCI)
      2014   Phase 1   NCT02211768   United States;
Magnetic resonance imaging
   Washington University School of Medicine
      2013   -   NCT02584413   United States;
Mekinist
   ErasmusMC
      2019   Phase 2   EUCTR2019-001317-16-NL   Netherlands;
   VO Barnmedicin, Skånes University Hospital
      2018   Phase 2   EUCTR2018-001846-32-SE   Sweden;
Methotrexate
   Children's Hospital of Philadelphia
      2001   Phase 2   NCT00030264   United States;
Methylphenidate
   Hospices Civils de Lyon
      2004   Phase 4   NCT00169611   France;
Mirdametinib (MEK Inhibitor)
   SpringWorks Therapeutics, Inc.
      2021   -   NCT05028166   -
Mirdametinib (PD-0325901) oral capsule or dispersible tablet
   SpringWorks Therapeutics, Inc.
      2019   Phase 2   NCT03962543   United States;
N-Acetyl cysteine
   Children's Hospital Medical Center, Cincinnati
      2020   Phase 2   NCT04481048   United States;
N-acetylcysteine (NAC)
   Children's Hospital Medical Center, Cincinnati
      2019   Phase 2   NCT04481035   United States;
NFX-179 Gel
   NFlection Therapeutics, Inc.
      2020   Phase 2   NCT04435665   United States;
NFX-179 gel
   NFlection Therapeutics, Inc.
      2021   Phase 2   NCT05005845   United States;
NILOTINIB HYDROCHLORIDE MONOHYDRATE
   Gustave Roussy
      2013   Phase 2   EUCTR2012-003005-10-DK   Denmark;France;Netherlands;Spain;Switzerland;
NPC-12G gel
   Nobelpharma
      2020   Phase 3   NCT04461886   Japan;
Nexavar
   Plymouth Hospital NHS Trust
      2011   Phase 4   EUCTR2011-001789-16-GB   United Kingdom;
Nexavar (BAY 43-9006) (Sorafenib)
   National Cancer Institute (NCI)
      2008   Phase 1   NCT00727233   United States;
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
   Mayo Clinic
      2017   Phase 1   NCT02700230   United States;
PD-0325901
   University of Alabama at Birmingham
      2014   Phase 2   NCT02096471   United States;
PTC299
   PTC Therapeutics
      2009   Phase 2   NCT00911248   United States;
Part 1 Levulan injection
   Harry T Whelan, MD
      2012   Phase 1   NCT01682811   United States;
Part 1 Levulan surface application twice with microneedling
   Harry T Whelan, MD
      2012   Phase 1   NCT01682811   United States;
Peg-Interferon alpha-2b
   Spectrum Health Hospitals
      2008   Phase 2   NCT00846430   United States;
Pharmacodynamics
   National Cancer Institute (NCI)
      2008   Phase 1   NCT00727233   United States;
Pirfenidone
   Mayo Clinic
      2000   Phase 2   NCT00754780   -
   National Cancer Institute (NCI)
      2004   Phase 2   NCT00076102   United States;
      2002   Phase 1   NCT00053937   United States;
Poly ICLC
   University of Alabama at Birmingham
      2021   Phase 2   NCT04544007   United States;
Pomalidomide
   National Cancer Institute (NCI)
      2015   Phase 1   NCT02415153   United States;
Propofol
   Medical College of Wisconsin
      2018   Phase 4   NCT03513757   United States;
QOL assessment, Neuropsychological
   National Cancer Institute (NCI)
      2008   Phase 1   NCT00727233   United States;
Quality-of-life assessment
   National Cancer Institute (NCI)
      2010   Phase 2   NCT01207687   United States;
RAD001
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      -   Phase 2   EUCTR2011-002228-42-FR   France;
   Assistance Publique - Hôpitaux de Paris
      2012   Phase 2   NCT01490476   France;
   NYU Langone Health
      2013   Early Phase 1   NCT01880749   United States;
   Novartis Pharmaceuticals
      -   Phase 4   EUCTR2016-001563-36-Outside-EU/EEA   Israel;
RAD001, everolimus
   Jonsson Comprehensive Cancer Center
      2015   Phase 2   NCT01345136   United States;
RAD001: Everolimus
   Assistance Publique - Hôpitaux de Paris
      2011   Phase 2   NCT01412892   France;
REC-2282
   Recursion Pharmaceuticals Inc.
      2021   Phase 2/Phase 3   NCT05130866   -
Radiofrequency
   Massachusetts General Hospital
      2021   Phase 1   NCT04730583   -
Radiographic Evaluation
   National Cancer Institute (NCI)
      2008   Phase 1   NCT00727233   United States;
Ranibizumab
   Massachusetts General Hospital
      2008   Phase 0   NCT00657202   United States;
Rapamycin
   Department of Dermatology Graduate School of Medicine, Osaka University
      2014   Phase 2,3   JPRN-UMIN000015081   Japan;
Saline Solution
   Fundação Educacional Serra dos Órgãos
      2017   Phase 2   NCT03090971   Brazil;
Selumetinib
   AstraZeneca
      2021   Phase 3   NCT04924608   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Russian Federation;Spain;United Kingdom;United States;
      2021   Phase 1   NCT05101148   Poland;Russian Federation;Spain;United States;
      2020   Phase 1   NCT04590235   China;
      2020   Phase 1   NCT04495127   Japan;
      2017   -   NCT03259633   United States;
   AstraZeneca KK
      2020   Phase 1   JPRN-JapicCTI-205422   Japan, North America;
   Children's Hospital Medical Center, Cincinnati
      2017   Phase 2   NCT03095248   United States;
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2019   Phase 1/Phase 2   NCT03326388   United Kingdom;
   National Cancer Institute (NCI)
      2016   Phase 2   NCT02407405   United States;
      2015   Phase 2   NCT02644512   United States;
      2010   Phase 1/Phase 2   NCT01089101   United States;
   Sarcoma Alliance for Research through Collaboration
      2019   Phase 2   NCT03433183   United States;
   Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
      2020   Phase 0   ChiCTR2000036770   China;
   University of Alabama at Birmingham
      2017   Phase 2   NCT03105258   United States;
   Yamaji Shigeyuki
      2021   Phase 3   JPRN-jRCT2041210036   Australia;Brasil;Canada;China;France;Germany;Italy;Japan;Netherland;Poland;Russia;Spain;UK;USA;
Selumetinib (AZD6244 hyd sulfate) 25mg/m2
   National Cancer Institute (NCI)
      2017   Phase 2   NCT03109301   United States;
Selumetinib (AZD6244 hyd sulfate) 50mg/dose
   National Cancer Institute (NCI)
      2017   Phase 2   NCT03109301   United States;
Selumetinib 10mg capsule
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-005607-39-IT   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States;
   AstraZeneca AB
      2021   Phase 3   EUCTR2020-005607-39-ES   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States;
      2021   Phase 1   EUCTR2020-005648-52-PL   Poland;Russian Federation;Spain;United States;
Selumetinib 25mg capsule
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-005607-39-IT   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States;
   AstraZeneca AB
      2021   Phase 3   EUCTR2020-005607-39-ES   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States;
      2021   Phase 1   EUCTR2020-005648-52-PL   Poland;Russian Federation;Spain;United States;
Selumetinib Hyd-sulphate
   Great Ormond Street Hospital
      2018   Phase 1;Phase 2   EUCTR2017-002635-41-GB   United Kingdom;
Selumetinib Sulfate
   National Cancer Institute (NCI)
      2020   Phase 3   NCT04166409   Canada;Puerto Rico;United States;
      2019   Phase 3   NCT03871257   Canada;Puerto Rico;United States;
      2017   Phase 2   NCT02839720   United States;
Selumetinib capsules
   AstraZeneca AB
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-NL   Germany;Italy;Netherlands;Russian Federation;Spain;United States;
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-ES   Germany;Italy;Netherlands;Russian Federation;Spain;United States;
      2021   Phase 1;Phase 2   EUCTR2020-005608-20-DE   Germany;Italy;Netherlands;Russian Federation;Spain;United States;
Selumetinib granules in sprinkle capsules for opening
   AstraZeneca AB
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-NL   Germany;Italy;Netherlands;Russian Federation;Spain;United States;
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-ES   Germany;Italy;Netherlands;Russian Federation;Spain;United States;
      2021   Phase 1;Phase 2   EUCTR2020-005608-20-DE   Germany;Italy;Netherlands;Russian Federation;Spain;United States;
Selumetinib hyd-sulfate
   ASTRAZENECA AB
      2021   Phase 3   EUCTR2020-005607-39-IT   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States;
   AstraZeneca AB
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-NL   Germany;Italy;Netherlands;Russian Federation;Spain;United States;
      2022   Phase 1;Phase 2   EUCTR2020-005608-20-ES   Germany;Italy;Netherlands;Russian Federation;Spain;United States;
      2021   Phase 3   EUCTR2020-005607-39-ES   Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;United States;
      2021   Phase 1;Phase 2   EUCTR2020-005608-20-DE   Germany;Italy;Netherlands;Russian Federation;Spain;United States;
      2021   Phase 1   EUCTR2020-005648-52-PL   Poland;Russian Federation;Spain;United States;
Selumetinib sulfate
   Great Ormond Street Hospital
      2018   Phase 1;Phase 2   EUCTR2017-002635-41-GB   United Kingdom;
Sevoflurane
   Medical College of Wisconsin
      2018   Phase 4   NCT03513757   United States;
Simvastatin 20mg/5ml Oral Suspension
   Central Manchester University Hospitals NHS Foundation Trust
      2013   Phase 2   EUCTR2012-005742-38-GB   United Kingdom;
Single Photon Emission Computed Tomography
   Mayo Clinic
      2017   Phase 1   NCT02700230   United States;
Sirolimus
   Osaka University Hospital
      2016   Phase 2   JPRN-UMIN000021030   Japan;
   Sarcoma Alliance for Research through Collaboration
      2019   Phase 2   NCT03433183   United States;
   University of Alabama at Birmingham
      2008   Phase 2   NCT00652990   United States;
      2008   Phase 2   NCT00634270   United States;
Skincerity plus sirolimus/rapamycin
   The University of Texas Health Science Center, Houston
      2009   Phase 1   NCT01031901   United States;
Skinercity plus sirolimus/rapamycin
   The University of Texas Health Science Center, Houston
      2009   Phase 1   NCT01031901   United States;
Sorafenib (as tosylate)
   Plymouth Hospital NHS Trust
      2011   Phase 4   EUCTR2011-001789-16-GB   United Kingdom;
Sunitinib
   Memorial Sloan Kettering Cancer Center
      2007   Phase 2   NCT00589784   United States;
Sutent®/Sunitinib
   Indiana University
      2012   Phase 2   NCT01402817   United States;
Tarceva and Rapamycin
   Roger Packer
      2007   Phase 1   NCT00901849   United States;
Tasigna
   Gustave Roussy
      2013   Phase 2   EUCTR2012-003005-10-DK   Denmark;France;Netherlands;Spain;Switzerland;
   Indiana University
      2011   Early Phase 1   NCT01275586   United States;
   Plymouth Hospital NHS Trust
      2011   Phase 4   EUCTR2010-023508-28-GB   United Kingdom;
Temozolomide (temodar)
   Spectrum Health Hospitals
      2008   Phase 2   NCT00846430   United States;
Temsirolimus
   M.D. Anderson Cancer Center
      2012   Phase 1   NCT01552434   United States;
Tipifarnib
   National Cancer Institute (NCI)
      2001   Phase 2   NCT00021541   Germany;United States;
Toxicity, Pharmacokinetics
   National Cancer Institute (NCI)
      2008   Phase 1   NCT00727233   United States;
Trametinib
   National Cancer Institute (NCI)
      2017   Phase 2   NCT03190915   United States;
   Novartis Pharmaceuticals
      2019   Phase 4   NCT03975829   Canada;France;Spain;United Kingdom;United States;
   Pediatric Brain Tumor Consortium
      2019   Phase 1/Phase 2   NCT04201457   United States;
   Region Skane
      2019   Phase 2   NCT03741101   Sweden;
   University of California, San Francisco
      2018   Phase 2   NCT03232892   United States;
Treatment A
   AstraZeneca
      2018   Phase 1   NCT03649165   United States;
Treatment B
   AstraZeneca
      2018   Phase 1   NCT03649165   United States;
Treatment C
   AstraZeneca
      2018   Phase 1   NCT03649165   United States;
Treatment D
   AstraZeneca
      2018   Phase 1   NCT03649165   United States;
Turalio
   National Cancer Institute (NCI)
      2015   Phase 1/Phase 2   NCT02390752   United States;
Unknown
   Leiden University Medical Center
      2021   Phase 2   EUCTR2020-000156-35-NL   Netherlands;
VINBLASTINE SULPHATE
   Gustave Roussy
      2013   Phase 2   EUCTR2012-003005-10-DK   Denmark;France;Netherlands;Spain;Switzerland;
Vehicle Gel
   NFlection Therapeutics, Inc.
      2020   Phase 2   NCT04435665   United States;
Vehicle gel
   NFlection Therapeutics, Inc.
      2021   Phase 2   NCT05005845   United States;
Vinblastine
   Children's Hospital of Philadelphia
      2001   Phase 2   NCT00030264   United States;
Vinblastine sulfate
   Children's Oncology Group
      2006   Phase 1   NCT00352495   Canada;United States;
Vincristine Sulfate
   National Cancer Institute (NCI)
      2020   Phase 3   NCT04166409   Canada;Puerto Rico;United States;
      2019   Phase 3   NCT03871257   Canada;Puerto Rico;United States;
Vincristine Sulfate (Oncovin)
   Spectrum Health Hospitals
      2008   Phase 2   NCT00846430   United States;
Votubia
   Novartis Pharmaceuticals
      -   Phase 4   EUCTR2016-001563-36-Outside-EU/EEA   Israel;
[18F]-FLT-PET/CT scans
   National Cancer Institute (NCI)
      2014   Phase 1   NCT02211768   United States;